PTC Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1,779	806.78	937.82	698.8	538.59	380.77
Revenue Growth (YoY)	97.54%	-13.97%	34.20%	29.75%	41.45%	24.04%
Cost of Revenue	503.24	591.88	732.05	696.17	573.01	442.99
Gross Profit	1,276	214.9	205.77	2.63	-34.42	-62.22
Selling, General & Admin	334.95	300.91	332.54	326	285.77	244.46
Amortization of Goodwill & Intangibles	18.7	60.74	222.64	116.55	54.75	36.89
Operating Expenses	353.65	361.65	555.18	442.55	340.52	281.36
Operating Income	922.26	-146.75	-349.4	-439.93	-374.94	-343.58
Interest Expense	-164.57	-170.39	-128.88	-90.87	-86.02	-56.35
Interest & Investment Income	23.07	-	-	-	-	-
Currency Exchange Gain (Loss)	-17.4	-	9	-31.3	-	-
Other Non Operating Income (Expenses)	107.34	98.12	2.81	-0.62	-45.19	51.63
EBT Excluding Unusual Items	870.7	-219.02	-466.48	-562.71	-506.15	-348.3
Merger & Restructuring Charges	1.49	-	-	-	-	-0.3
Gain (Loss) on Sale of Investments	16.67	11.73	-1.98	-17.29	-12.69	33.56
Asset Writedown	-168.55	-168	-217.8	-33.38	-	-54
Other Unusual Items	16.5	12.18	-9.86	25.9	0.5	-33.89
Pretax Income	741	-363.12	-696.11	-587.49	-518.34	-402.93
Income Tax Expense	-10.72	0.18	-69.51	-28.47	5.56	35.23
Net Income	751.72	-363.3	-626.6	-559.02	-523.9	-438.16
Net Income to Common	751.72	-363.3	-626.6	-559.02	-523.9	-438.16
Shares Outstanding (Basic)	78	77	75	72	70	66
Shares Outstanding (Diluted)	84	77	75	72	70	66
Shares Change (YoY)	10.56%	2.68%	4.33%	1.79%	6.72%	12.17%
EPS (Basic)	9.60	-4.73	-8.37	-7.79	-7.43	-6.64
EPS (Diluted)	8.94	-4.73	-8.37	-7.79	-7.43	-6.64
Free Cash Flow	705.21	-114.19	-186.86	-388.67	-279.55	-211.91
Free Cash Flow Per Share	8.35	-1.49	-2.50	-5.42	-3.97	-3.21
Gross Margin	71.71%	26.64%	21.94%	0.38%	-6.39%	-16.34%
Operating Margin	51.84%	-18.19%	-37.26%	-62.95%	-69.62%	-90.23%
Profit Margin	42.25%	-45.03%	-66.81%	-80.00%	-97.27%	-115.07%
Free Cash Flow Margin	39.64%	-14.15%	-19.92%	-55.62%	-51.90%	-55.66%
EBITDA	954.94	-71.08	-112.81	-311.09	-310.81	-300.09
EBITDA Margin	53.67%	-8.81%	-12.03%	-44.52%	-57.71%	-78.81%
D&A For EBITDA	32.68	75.66	236.59	128.84	64.13	43.49
EBIT	922.26	-146.75	-349.4	-439.93	-374.94	-343.58
EBIT Margin	51.84%	-18.19%	-37.26%	-62.95%	-69.62%	-90.23%
Revenue as Reported	1,779	806.78	937.82	698.8	538.59	380.77

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q